Workflow
What Analyst Projections for Key Metrics Reveal About Gilead (GILD) Q1 Earnings
GILDGilead(GILD) ZACKS·2025-04-18 14:20

Core Viewpoint - Analysts expect Gilead Sciences to report quarterly earnings of 1.73pershare,reflectingayear−over−yearincreaseof231.11.73 per share, reflecting a year-over-year increase of 231.1%, with revenues projected at 6.83 billion, up 2.2% from the previous year [1]. Earnings Estimates - The consensus EPS estimate has been revised upward by 0.9% in the past 30 days, indicating a reassessment of initial estimates by covering analysts [1][2]. Revenue and Product Sales Projections - Total product sales are expected to reach 6.75billion,indicatingayear−over−yearchangeof+1.66.75 billion, indicating a year-over-year change of +1.6% [4]. - Royalty contract and other revenues are estimated at 40.04 million, reflecting a +2.7% change from the prior year [4]. - Product Sales for HIV (Genvoya) are projected at 375.96million,showingadeclineof−6.7375.96 million, showing a decline of -6.7% year over year [4]. - Product Sales for HIV (Odefsey) are expected to be 294.72 million, down -4.9% from the previous year [5]. - Oncology product sales (Tecartus) are forecasted at 56.12million,indicatinga+256.12 million, indicating a +2% change [5]. - Liver Disease product sales (Sofosbuvir/Velpatasvir) are estimated at 238.12 million, down -4% from the year-ago quarter [6]. - Other product sales (Other) are projected at 40.07million,reflectingasignificantdeclineof−32.140.07 million, reflecting a significant decline of -32.1% [6]. - Total HIV product sales in the U.S. are expected to reach 3.56 billion, indicating a +4.6% change year over year [7]. Additional Product Sales Insights - Product Sales for HIV (Genvoya) in the U.S. are projected at 299.29million,down−9.9299.29 million, down -9.9% from the previous year [7]. - Liver Disease product sales (Vemlidy) are expected to be 96.60 million, reflecting a +1.7% change [8]. - Other product sales (AmBisome) are projected at 11.31million,down−19.211.31 million, down -19.2% from the prior year [8]. - Product Sales for Veklury are expected to be 277.30 million, indicating a -12% change year over year [8]. Stock Performance - Gilead shares have experienced a -1.3% change over the past month, compared to a -6.9% move in the Zacks S&P 500 composite [9].